Intravitreal cell-based production of glucagon-like peptide-1

Retina

Volumn 31, Issue 4, 2011, Pages 785-789

  Zhang, Rong ^a   Zhang, Haijuan ^a   Xu, Liang ^a   Ma, Ke ^a   Wallrapp, Christine ^b   Jonas, Jost B ^a,c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CellMed AG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BARIUM; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOLOGY; MICROSCOPY; NONHUMAN; RAT; RETINA; SAFETY; SPRAGUE DAWLEY RAT; VITREOUS BODY;

ANIMALS; APOPTOSIS; CELL LINE; DRUG DELIVERY SYSTEMS; ENTEROENDOCRINE CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCAGON-LIKE PEPTIDE 1; IN SITU NICK-END LABELING; INCRETINS; MICROSPHERES; RATS; RATS, SPRAGUE-DAWLEY; VITREOUS BODY;

EID: 79955062922     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181f27509     Document Type: Article

References (27)

1. Machemer R, Sugita G, Tano Y. Teatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180. (Pubitemid 10072805)
2. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular edematous and neovascular diseases. Acta Ophthalmol; 2005;83:645-663. (Pubitemid 41819287)
3. Degenring RF, Jonas JB. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004; 137:1142-1143. (Pubitemid 38759374)
4. Jonas JB, Kamppeter B, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema. A prospective randomized study. J Ocul Pharmakol Th 2006;22:200-207. (Pubitemid 44051133)
5. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-673. (Pubitemid 36554469)
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
8. Schindler RH, Chandler DB, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93;415-417. (Pubitemid 12143608)
9. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal re-injection of triamcinolone for exudative age- related macular degeneration. Arch Ophthalmol 2004;122: 218-222. (Pubitemid 38176489)
10. Jonas JB, Degenring RF, Kreissig I, Akkoyun I. Safety of intravitreal high-dose re-injections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-1055. (Pubitemid 40040030)
11. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and Neuroprotection. Nat Med 2003;9:1173-1179. (Pubitemid 37173702)
12. Perry T, Holloway HW, Weerasuriya A, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301. (Pubitemid 46157226)
13. Coppen, D. Biocompatibles International plc: local drug delivery for targeted therapies. Regenerative Medicine, March 2010, Vol. 5, No. 2, Pages. 189-195.
14. Heile A, Wallrapp C, Klinge P, et al. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neuroscience Letters 2009,463:176-181
15. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
16. Negoescu A, Lorimier P, Labat-Moleur F, et al. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996;44:959-968. (Pubitemid 26293367)
17. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292-3298.
18. Thanos CG, Bell WJ, O ́ Rourke P, et al. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng 2004;10:1617-1622. (Pubitemid 40054203)
19. Bush RA, Lei B, Tao W, et al. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci 2004;45:2420-2430. (Pubitemid 38902618)
20. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103:3896-3901. (Pubitemid 43376652)
21. Beltran WA, Allore HG, Johnson E, et al. CREB1/ATF1 activation in photoreceptor degeneration and protection. Invest Ophthalmol Vis Sci 2009;50:5355-5363.
22. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006;6: 717-726.
23. Lee M, Lo AC, Cheung PT, Wong D, Chan BP. Drug carrier systems based on collagen-alginate composite structures for improving the performance of GDNF-secreting HEK293 cells. Biomaterials 2009;30:1214-1221.
24. Tielsch JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population: the Baltimore Eye Survey. Arch Ophthalmol 1990;108: 286-290. (Pubitemid 20058168)
25. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in an urban and rural area in Beijing: the Beijing Eye Study. Ophthalmology 2006;113:1141.e1-3
26. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009;106:1285-1290.
27. Zhang R, Ma K, Xu L, et al. Intraocular cell-based production of glucagon-like peptide-1 in the anterior chamber. Acta Ophthalmol. 2009 November 23. [Epub ahead of print].